These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 10745253

  • 1. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T, Ilhan O, Mandel NM, Arat M, Günel N, Celebi H, Ustün C, Akan H, Demirer S, Aydintuğ S, Uysal A, Koç H.
    Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH, Bensinger WI, Appelbaum FR, Lilleby K, Sandmaier B, Brunvand M, Rowley S, Petersdorf S, Rivkin S, Gooley T.
    Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
    [Abstract] [Full Text] [Related]

  • 3. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
    Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S, Arslan O, Gurman G, Akan H, Ilhan O.
    Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
    Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA, Weaver CH, Demirer T, Sanders JE, Petersdorf S, Gooley T, Weiden P, Zuckerman N, Montgomery P, Maziarz R, Klarnet JP, Rivkin S, Trueblood K, Storb R, Holmberg L, Buckner CD.
    Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
    [Abstract] [Full Text] [Related]

  • 5. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
    Demirer T, Uysal VA, Ayli M, Genc Y, Ilhan O, Koc H, Dagli M, Arat M, Gunel N, Fen T, Dincer S, Ustael N, Yildiz M, Ustun T, Seyrek E, Ozet G, Muftuoglu O, Akan H.
    Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
    [Abstract] [Full Text] [Related]

  • 6. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM, Gray R, Ciobanu N, Winter J, Weiner RS.
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [Abstract] [Full Text] [Related]

  • 8. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
    Weaver CH, Greco FA, Hainsworth JD, Zhen B, Baldwin P, Wittlin F, Lewis M, West WH, Schwartzberg L, Buckner CD.
    Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925
    [Abstract] [Full Text] [Related]

  • 9. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK, Elfenbein GJ, Perkins JB, Janssen WE, Ballester OF, Hiemenz JW, Zorsky PE, Kronish LE, Foody MC.
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [Abstract] [Full Text] [Related]

  • 10. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
    Sola Rocabert C, Mesía R, Mendoza L, Tabernero JM, Amill B, Maroto P, Bellet M, Ojeda B, Alonso MC, Verger G.
    Med Clin (Barc); 1995 Oct 07; 105(11):407-11. PubMed ID: 7475451
    [Abstract] [Full Text] [Related]

  • 11. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM, Grinblatt DL, Malloy R, Williams SF.
    Cancer; 1998 Oct 15; 83(8):1540-5. PubMed ID: 9781947
    [Abstract] [Full Text] [Related]

  • 12. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M, Yoshizawa H, Tanaka H, Tanaka J, Kagamu H, Ito K, Shimbo T, Chou D, Wakabayashi M, Suzuki E, Sakai K, Arakawa M, Gejyo F.
    Bone Marrow Transplant; 2000 Jan 15; 25(1):5-11. PubMed ID: 10654007
    [Abstract] [Full Text] [Related]

  • 13. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.
    Bone Marrow Transplant; 2001 Feb 15; 27(3):269-78. PubMed ID: 11277174
    [Abstract] [Full Text] [Related]

  • 14. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
    Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A, Ascensao JL.
    Bone Marrow Transplant; 1997 May 15; 19(10):983-8. PubMed ID: 9169642
    [Abstract] [Full Text] [Related]

  • 15. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
    Fleischhack G, Pöpping K, Hasan C, Utsch B, Jüttner J, Bode U.
    Klin Padiatr; 1998 May 15; 210(4):248-55. PubMed ID: 9743961
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
    Fields KK, Elfenbein GJ, Perkins JB, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Kronish LE, Foody MC.
    Semin Oncol; 1993 Oct 15; 20(5 Suppl 6):59-66. PubMed ID: 8211217
    [Abstract] [Full Text] [Related]

  • 18. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI.
    Biol Blood Marrow Transplant; 1997 Nov 15; 3(5):261-6. PubMed ID: 9450921
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S.
    Bone Marrow Transplant; 2001 Jul 15; 28(2):173-80. PubMed ID: 11509935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.